Neonatal Jaundice: Transcutaneous Bilirubin Screening Accuracy

Neonatal jaundice is common, but clinically significant hyperbilirubinaemia can progress quickly in the first days after birth. A yellow appearance alone cannot show how high the bilirubin concentration is, so timely screening is essential for identifying babies who need laboratory testing, closer observation or phototherapy.

Transcutaneous bilirubinometry offers a fast, non-invasive way to estimate bilirubin through the skin. Its value is greatest when it is used as a screening tool within a clear clinical pathway, rather than as a replacement for serum bilirubin measurement when treatment may be required.

How Screening Methods Compare

A TcB device measures yellow pigmentation in the skin using reflected light. The reading is converted into an estimated bilirubin concentration, usually reported in micromoles per litre in Australia. It can reduce unnecessary heel pricks and help staff identify babies who require a total serum bilirubin, or TSB, test.

The test does not remove the need for clinical judgement. A newborn’s age in hours, gestational age, rate of bilirubin rise, feeding pattern, weight change and medical history all affect risk. A result that appears reassuring in isolation may require action when the baby is only 30 hours old, is feeding poorly or has known haemolysis.

Understanding Transcutaneous Bilirubinometry

Most devices use optical wavelengths to estimate bilirubin in the subcutaneous tissue. Staff generally take several readings from the sternum or forehead and follow the manufacturer’s instructions for the selected device. The instrument is fast, does not disturb sleep and can be used before discharge or during community follow-up.

Accuracy is usually reasonable across a broad range of bilirubin values, especially below the phototherapy threshold. However, TcB is an estimate rather than a direct blood measurement. Different devices have different bias patterns, and readings should not be compared casually between models or treated as interchangeable with laboratory results.

Skin thickness, pigmentation, bruising, vernix, oedema and recent phototherapy can affect performance. A device may also be less dependable in a very preterm infant or a baby with unusual skin characteristics. Training should cover site selection, cleaning, calibration checks and documentation of the instrument used.

What Accuracy Really Means

Accuracy includes several concepts. Bias describes whether a device tends to read higher or lower than the serum value. Precision describes how closely repeated readings agree with one another. Sensitivity is important when screening because a false-negative result could delay treatment, while specificity helps avoid unnecessary blood tests.

A TcB value close to the age-specific phototherapy line should therefore be treated cautiously. Many clinical protocols recommend obtaining a TSB when the transcutaneous result is within a defined margin of the treatment threshold, commonly around 50 micromol/L, although local guidance and the device’s validation data must be followed.

A rising TcB trend may be more informative than a single number, particularly when feeding and output are also being monitored. A rapid increase can suggest increased bilirubin production or insufficient intake. Even so, an apparent trend should be confirmed with serum testing when it approaches a treatment line or when the baby’s condition changes.

Moving From A Reading To A Decision

Interpretation begins with the baby’s postnatal age in hours, not simply the day of life. Bilirubin nomograms and treatment charts account for this timing. A level that is acceptable at 72 hours may be concerning at 24 hours, and thresholds can differ according to gestational age and neurotoxicity risk factors.

The clinician should assess jaundice in the context of haemolysis, sepsis, bruising, cephalohaematoma, glucose-6-phosphate dehydrogenase deficiency and poor enteral intake. Babies born at less than 38 weeks’ gestation generally require more cautious surveillance. Dark urine, pale stools, lethargy, hypotonia, fever or difficulty waking for feeds warrant urgent assessment rather than routine repeat screening.

When a confirmatory TSB is indicated, the blood result should be plotted on the appropriate local chart. Treatment decisions should be based on the serum value and the relevant threshold, not on a visual estimate or an isolated TcB reading. Phototherapy, feeding support and further investigation can then be started without avoidable delay.

Applying The Pathway In Australia

Australian maternity services vary widely. A large tertiary unit such as the Royal Children’s Hospital Melbourne can arrange rapid laboratory testing and neonatal review, while a rural or remote service may need to coordinate transport, telehealth support or transfer to a regional hospital. A reliable screening protocol must work in both settings.

The national newborn bloodspot screening program is often called the heel-prick test, but it is not a substitute for bilirubin screening. Families may reasonably assume that one newborn blood test checks everything. Midwives, child and family health nurses and Aboriginal health workers should explain that bilirubin assessment is a separate process.

Discharge planning is particularly important in Australia because families may leave hospital early and travel long distances home. In Sydney, Brisbane or Melbourne, a follow-up appointment may be straightforward; in parts of the Northern Territory, Western Australia or far north Queensland, access to pathology and paediatric review can be limited. The discharge plan should specify when bilirubin will be checked, who receives the result and where the family should go if jaundice worsens.

Local services should use their state or territory neonatal guidance, laboratory reference ranges and escalation arrangements. Australian parents may hear terms such as “maternal and child health nurse,” “community midwife” or “neonatal outreach,” so written information should name the actual service and provide a telephone pathway rather than relying on general advice.

Babies Who Need Extra Care

Prematurity, low birth weight and haemolytic disease increase the risk of bilirubin neurotoxicity. Blood group incompatibility, a positive direct antiglobulin test, significant bruising or a rapid bilirubin rise should lower the threshold for serum confirmation. TcB can still assist with screening, but it should not delay laboratory testing in a high-risk infant.

Feeding assessment is central. Suboptimal intake can increase enterohepatic circulation and contribute to dehydration-associated jaundice. Clinicians should record latch, transfer, frequency of feeds, urine, stool transition and weight change. Supplementation decisions need to be individualised, with lactation support provided rather than presenting formula as the only solution.

Medication exposure and maternal illness can complicate assessment. A review of maternal immunosuppressive therapy may be relevant when considering an infant’s broader neonatal examination, infection risk and follow-up needs. It does not replace a bilirubin assessment, but it reminds clinicians to interpret jaundice alongside the complete perinatal history.

Babies who have received phototherapy require particular caution because TcB values can be affected by treatment-related changes in the skin. A serum measurement is generally preferred when checking rebound bilirubin or deciding whether treatment can safely stop. The exact approach depends on gestational age, cause of jaundice and the treating service’s protocol.

Making Screening Safer And More Consistent

Every service using TcB should define who can perform the test, which body site is used, how many readings are taken and when TSB confirmation is mandatory. Devices need scheduled quality assurance, cleaning and maintenance. Results should be entered into the newborn record with the time of measurement, baby’s age in hours and any relevant treatment already given.

Electronic systems can improve safety by linking a bilirubin result to gestational age and postnatal age. Alerts are useful when a reading is near the treatment line, but they should support rather than replace trained review. A documented handover is essential when a baby moves from hospital to a GP clinic, community midwifery service or rural hospital.

Family communication is part of accurate screening. Parents should know that jaundice often peaks between the third and fifth day, that frequent feeding supports intake and that sunlight is not a safe substitute for prescribed phototherapy. They should be told to seek urgent care if the baby is difficult to wake, feeds poorly, becomes floppy, develops worsening yellowing or produces dark urine or pale stools.

Professional education and audit can reveal whether confirmatory blood tests are being ordered at the right point. Services can review false-negative screens, delayed treatment, unnecessary heel pricks, readmissions and follow-up failures. The wider scientific and perinatal context represented by the FAOPS 2020 congress site also reflects why shared research, consistent terminology and collaboration across neonatal services matter.

Accurate TcB screening depends on a complete pathway: competent measurement, age-specific interpretation, prompt serum confirmation and reliable follow-up. Australian hospitals, community services and remote teams can improve outcomes by making each step visible to clinicians and families. Build the process into local newborn care protocols, train staff to recognise its limits and arrange bilirubin review before every at-risk baby leaves the service.